Abstract:Objective To analyze the correlation between serum uric acid (UA) and matrix metalloproteinase-3 (MMP-3) levels and the efficacy of GINKGO dipyridamole in the treatment of large atherosclerotic ischemic stroke, and to evaluate the value of serum indicators to predict the efficacy.Methods The clinical data of 82 patients with aortic ischemic stroke who were treated with GINKGO dipyridamole in our hospital from February 2018 to November 2019 were retrospectively analyzed and divided into group A (Basic cure, n = 18), group B (significant effect, n = 35), group C (effective, n = 20), and group D (ineffective, n = 9), according to the treatment effect. Serum levels of UA, MMP-3, homocysteine, and interleukin-10 (IL-10) were measured and compared in each group. The receiver operating characteristic curve (ROC) was drawn to test the value of each index used to predict the curative effect.Results Levels of UA, MMP-3, and Hcy in group D > group C > group B > group A, and IL-10 level in group D < group C < group B < group A, with the difference is statistically significant (P < 0.05); uric acid, MMP-3, and Hcy levels were negatively correlated with the efficacy (r =-0.524, -0.486, -0.245, all P < 0.05), and IL-10 was positively correlated with the efficacy (r = 0.781, P < 0.05); the sensitivity of uric acid, MMP-3, Hcy, and IL-10 to predict the therapeutic effect of ginkgo dipyridamole on ischemic stroke was 0.902, 0.845, 0.713, and 0.685, respectively, and the specificity were 0.785, 0.781, 0.684, and 0.684, respectively.Conclusions Serum UA and MMP-3 levels can be used as serological indicators to predict the efficacy of GINKGO dipyridamole in the treatment of aortic atherosclerotic ischemic stroke, and the levels of the two are negatively correlated with the curative effect. Hence, it is necessary to actively adjust the serum UA and MMP-3 levels of patients during clinical treatment.